A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients With Late-Stage HIV Disease

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if it is safe and effective to give WF10 to adults with late-stage HIV disease. WF10 is suspected to help the immune system fight infection and slow HIV disease progression.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OXO Chemie

Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Are HIV-positive.

• Have a CD4 cell count of less than 50 cells/mm3 within 14 days prior to study entry.

• Are at least 18 years old.

• Have received anti-HIV drugs at some time in the past.

• Agree to practice abstinence or use effective methods of birth control, including the pill, during the study.

Exclusion Criteria

Patients will not be eligible for this study if they:

• Are being treated for any form of cancer within 30 days of study entry.

• Have ever received an HIV vaccine.

• Have received steroids within 30 days prior to study entry. (Note: Testosterone is allowed.)

• Have received certain medications, including anti-HIV treatments that are not approved by the FDA.

• Have participated in another WF10 study.

• Have an illness or any condition that might exclude them from this study.

• Are pregnant or breast-feeding.

• Abuse drugs or medications.

• Received a blood transfusion within 45 days prior to study entry.